European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Cystic Fibrosis in People Ages 12 Years and OlderBusiness Wire • 08/21/20
Stock Upgrades: Vertex Pharmaceuticals Shows Rising Relative StrengthInvestors Business Daily • 08/18/20
Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 07/31/20
Vertex Pharmaceuticals (VRTX) Tops Q2 Earnings and Revenue EstimatesZacks Investment Research • 07/30/20
Vertex Pharmaceuticals: 67% YoY Returns With 4% Downside Risk - Calling All Medium-Term PlayersSeeking Alpha • 07/28/20
Stocks To Watch With Next Quarterly Report On Tap: Vertex PharmaceuticalsInvestors Business Daily • 07/24/20
Goldman Sachs Sees Big Gains From 7 Biotech & Pharma Conviction Buy Stocks24/7 Wall Street • 07/24/20
Positive Phase 3 Study Results for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in People Ages 12 and Older With Cystic Fibrosis Who Have One Copy of the F508del Mutation and One Gating or Residual Function MutationBusiness Wire • 07/20/20
Tax software company Vertex to offer 21.2 million shares in planned IPO, priced at $14 to $16 eachMarket Watch • 07/20/20